Acquisition to boost Genzyme's surgical business
This article was originally published in Clinica
Genzyme's General Division plans to acquire Deknatel Snowden Pencer (DSP), a privately-held surgical products company, for $250 million in cash. The proposed purchase, which is expected to close by the end of June, should add $50 million to Genzyme's revenue this year. Genzyme's 1995 turnover was $379 million.
You may also be interested in...
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.